Heparin Shortage Update: What Patients Need to Know in 2026

Heparin — one of the most essential anticoagulant medications in modern medicine — has been on the FDA's official drug shortage list continuously since November 2017. That's over eight years of unresolved supply disruptions. For patients who rely on heparin injections at home, the situation in 2026 remains challenging, with multiple manufacturers reporting backorders, production delays, and discontinued product lines. This article provides the most up-to-date patient-focused summary of what's happening and what it means for you.

Current Shortage Status (2026)

As of early 2026, the ASHP drug shortage database confirms that heparin injection remains in shortage across multiple formulations and manufacturers. Key developments include:

Mylan (Viatris): Permanently discontinued all heparin injection products in March and April 2025. These products will not return to market.

Pfizer: Shortage due to increased demand and manufacturing delays. Several formulations temporarily discontinued. Carpuject syringes (5,000 and 10,000 units/mL) in limited supply with weekly releases. An Important Drug Warning Letter was issued regarding potential molding defects in some Carpuject needle sheaths — patients should visually inspect units before use.

Sagent: 1,000 units/mL 10 mL vials on backorder with April 2026 estimated release. 30 mL vials on limited allocation.

Techdow USA: 10,000 units/mL and 20,000 units/mL vials on backorder with no estimated release date provided.

Better availability: Fresenius Kabi and Hikma remain the most reliably available manufacturers in most regions, though stock can still vary week-to-week at individual pharmacies.

What Is Driving the Heparin Shortage?

The heparin shortage has multiple, interconnected root causes that make it particularly difficult to resolve quickly:

Animal-sourced production: Heparin is extracted from porcine (pig) intestinal mucosa. About 60% of the U.S. supply comes from China. Disease outbreaks, farming capacity changes, or geopolitical disruptions can affect the upstream supply chain.

Tariff pressure: U.S. tariffs on Chinese pharmaceutical imports are increasing cost pressure on manufacturers, potentially making some formulations less economically viable to continue producing.

Manufacturing complexity: Producing heparin requires specialized, expensive equipment that processes enormous volumes of biological starting material. New manufacturing capacity cannot be spun up quickly.

High, inelastic demand: An estimated 50-70% of hospitalizations require heparin, and patients who need it for dialysis or anticoagulation cannot substitute other medications without careful medical supervision.

Which Patients Are Most Affected?

The heparin shortage most directly impacts patients who rely on outpatient or home heparin injection:

Patients on bridge therapy (transitioning between anticoagulants)

Pregnant women who cannot take warfarin or DOACs and need injectable anticoagulation

Patients with mechanical heart valves requiring ongoing anticoagulation

Patients who have had prior DVT/PE and cannot tolerate oral alternatives

For hospital inpatients, heparin access is primarily managed by the hospital pharmacy and healthcare team. Outpatients filling prescriptions at retail pharmacies face the greatest challenges.

What Should Patients Do Right Now?

Start searching for refills early — at least 7-10 days before you need the medication

Contact your prescriber — ask if a different heparin formulation or strength is acceptable, or discuss alternatives

Use medfinder — we call pharmacies near you to check which ones have your medication in stock, so you don't have to

Check independent pharmacies — these often have stock that chain pharmacies have depleted

37,598+ patients found their medications in stock

37K+

Find Heparin In Stock Today →

Is the Heparin Shortage Expected to Improve?

The FDA has acknowledged the shortage and is working with manufacturers to mitigate supply disruptions. The agency has also indicated it will support the development of non-porcine heparin alternatives, including synthetic versions. However, these structural changes take years. Patients should plan for ongoing supply variability throughout 2026.

If you cannot find heparin at your local pharmacy, medfinder can search pharmacies near you on your behalf. And if your prescriber needs to consider alternatives, see our guide on alternatives to heparin if you can't fill your prescription.